Why this matters
- Neuroendocrine cancer (NEC) incidence is increasing. Most common in the Netherlands and Canada and least in Japan and Taiwan.
- Bile Duct Cancer (BDC) also a rare cancer with increasing incidence. Highest prevalence in Thailand, South Korea, China, Japan, Italy, and the UK.
- New WHO tumor classification: G1 Ki-67 index changed to
- TELESTAR/TELECAST: EMA approved telotistrat ethyl (Xermelo) for carcinoid syndrome diarrhea inadequately controlled by SSA.
- NETTER-1: in progressive midgut NET, EMA approved 177Lu-DOTATOC (Lutathera) for gastroenteropancreatic neuroendocrine tumors.
- RADIANT-4: first study on QoL with Everolimus in non-functional GI or lung NET did not show improvement compared to placebo.
- Sunitinib phase IV trial: activity supported in advanced pancreatic NET.
- Adjuvant therapy phase III BCAT study showed no benefit from gemcitabine.
- On advanced disease: Phase III FUGA-BT study showed gem/S1 is a new option for Japanese patients.
- International Cancer Genome Consortium improved understanding of genetic environment of BDC: intra vs extra hepatic carcinomas have different mutation profiles (liver vs non liver associated, and inflammatory vs proliferative subclasses) which are tied to therapeutic and prognostic implications.